Germline pathogenic variants in neuroblastoma patients are enriched in BARD1 and predict worse survival.

MLA

Kim, Jung, et al. “Germline Pathogenic Variants in Neuroblastoma Patients Are Enriched in BARD1 and Predict Worse Survival.” Journal of the National Cancer Institute, vol. 116, no. 1, Jan. 2024, pp. 149–59. EBSCOhost, https://doi.org/10.1093/jnci/djad183.

APA

Kim, J., Vaksman, Z., Egolf, L. E., Kaufman, R., Evans, J. P., Conkrite, K. L., Danesh, A., Lopez, G., Randall, M. P., Dent, M. H., Farra, L. M., Menghani, N. L., Dymek, M., Desai, H., Hausler, R., Hicks, B., Guidry Auvil, J., Gerhard, D. S., Hakonarson, H., … Diskin, S. J. (2024). Germline pathogenic variants in neuroblastoma patients are enriched in BARD1 and predict worse survival. Journal of the National Cancer Institute, 116(1), 149–159. https://doi.org/10.1093/jnci/djad183

Chicago

Kim, Jung, Zalman Vaksman, Laura E Egolf, Rebecca Kaufman, J Perry Evans, Karina L Conkrite, Arnavaz Danesh, et al. 2024. “Germline Pathogenic Variants in Neuroblastoma Patients Are Enriched in BARD1 and Predict Worse Survival.” Journal of the National Cancer Institute 116 (1): 149–59. doi:10.1093/jnci/djad183.